Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Receivables (2016 - 2026)

Champions Oncology (CSBR) has 13 years of Change in Receivables data on record, last reported at $2.1 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 69.08% year-over-year to $2.1 million; the TTM value through Oct 2025 reached $1.1 million, down 59.71%, while the annual FY2025 figure was $1.4 million, 27.88% down from the prior year.
  • Change in Receivables reached $2.1 million in Q4 2025 per CSBR's latest filing, up from -$1.8 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.3 million in Q1 2025 and bottomed at -$4.5 million in Q2 2025.
  • Average Change in Receivables over 5 years is $314200.0, with a median of $311000.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: plummeted 353.49% in 2023, then skyrocketed 2500.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $496000.0 in 2021, then plummeted by 155.65% to -$276000.0 in 2022, then plummeted by 317.39% to -$1.2 million in 2023, then surged by 206.68% to $1.2 million in 2024, then surged by 69.08% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $2.1 million in Q4 2025, -$1.8 million in Q3 2025, and -$4.5 million in Q2 2025.